Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011‐vcMMAE antibody‐drug conjugate

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Molecular Oncology

• Publication date

  2008-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.molonc.2008.02.002PMID 19383330PMCID PMC5527796
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011‐vcMMAE antibody‐drug conjugate

  2008cited by this paper
• ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro.

  2007cited by this paper
• Comprehensive Expression Profiling of Tumor Cell Lines Identifies Molecular Signatures of Melanoma Progression

  2007cited by this paper
• Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer

  2007cited by this paper
• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

  2007influential reference
• Melanoma biology and new targeted therapy

  2007cited by this paper
• Suppression of BRAF/MEK/MAP Kinase Pathway Restores Expression of Iodide-Metabolizing Genes in Thyroid Cells Expressing the V600E BRAF Mutant

  2007cited by this paper
• Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.

  2007cited by this paper
• MAP kinase signalling pathways in cancer

  2007cited by this paper
• Treatment parameters modulating regression of human melanoma xenografts by an antibody–drug conjugate (CR011-vcMMAE) targeting GPNMB

  2007cited by this paper
• Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

  2007cited by this paper
• Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein

  2007influential reference
• Glycoprotein Nonmetastatic Melanoma Protein B, a Potential Molecular Therapeutic Target in Patients with Glioblastoma Multiforme

  2006cited by this paper
• Mutation analysis of 24 known cancer genes in the NCI-60 cell line set

  2006cited by this paper
• CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.

  2006cited by this paper
• Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.

  2006cited by this paper
• p38 kinase regulates epidermal growth factor receptor downregulation and cellular migration

  2006cited by this paper
• Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression

  2006cited by this paper
• Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

  2006cited by this paper
• BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin

  2005cited by this paper
• Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas

  2004cited by this paper
• Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo.

  2004cited by this paper
• Signals for sorting of transmembrane proteins to endosomes and lysosomes.

  2003cited by this paper
• The ADAMs family of metalloproteases: multidomain proteins with multiple functions.

  2003cited by this paper
• Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase

  2002cited by this paper
• Transmodulation of Cell Surface Regulatory Molecules via Ectodomain Shedding

  2002cited by this paper
• Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice

  2002cited by this paper
• Improving the efficacy of antibody-based cancer therapies

  2001influential reference
• Dissection of Ras-Dependent Signaling Pathways Controlling Aggressive Tumor Growth of Human Fibrosarcoma Cells: Evidence for a Potential Novel Pathway

  2000cited by this paper
• Inhibition of the Mitogen-activated Protein Kinase Pathway Triggers B16 Melanoma Cell Differentiation*

  1998cited by this paper
• Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.

  1998cited by this paper
• Potentiation of antitumor immunotoxins by liposomal monensin.

  1993cited by this paper

• GPNMB promotes tumor growth and is a biomarker for lymphangioleiomyomatosis.

  2024cites this paper
• Antibody–Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations

  2024cites this paper
• ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer

  2023cites this paper
• Radiation dosimetry of 89Zr labeled antibody estimated using the MIRD method and MCNP code

  2022cites this paper
• Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies

  2022cites this paper
• HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin

  2022cites this paper
• N‐glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC

  2021cites this paper
• Identification of Significant Gene Expression Changes in Multiple Perturbation Experiments using Knockoffs

  2021cites this paper
• Functional characterization of Gpnmb in inflammatory and metabolic diseases

  2020cites this paper
• A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma

  2020cites this paper
• Antibody-drug conjugates: an evolving approach for melanoma treatment.

  2020cites this paper
• 111In-Labeled Glycoprotein Nonmetastatic b (GPNMB) Targeted Gemini Surfactant-Based Nanoparticles against Melanoma: In Vitro Characterization and in Vivo Evaluation in Melanoma Mouse Xenograft Model.

  2019cites this paper
• Towards new personalized treatment options for patients with genomically unstable tumors

  2019cites this paper
• A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma

  2019cites this paper
• Genome-wide expression analysis reveals six contravened targets of EZH2 associated with breast cancer patient survival

  2019cites this paper
• Antibody-Drug Conjugates: Possibilities and Challenges

  2019cites this paper
• Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer

  2018cites this paper
• Glycoprotein nmb Is Exposed on the Surface of Dormant Breast Cancer Cells and Induces Stem Cell-like Properties.

  2018cites this paper
• Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma.

  2018cites this paper
• Novel Targeted Therapies for Metastatic Melanoma

  2017cites this paper
• GPNMB promotes proliferation of developing eosinophils

  2017cites this paper
• Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer☆

  2017cites this paper
• Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent

  2017cites this paper
• Glycoprotein Non‐Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target

  2017influential citation
• Research Progress in Oncology. Highlighting and Exploiting the Roles of Several Strategic Proteins in Understanding Cancer Biology

  2016cites this paper
• MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB

  2016cites this paper
• Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.

  2016cites this paper
• Growth and repair factors, osteoactivin, matrix metalloproteinase and heat shock protein 72, increase with resolution of inflammation in musculotendinous tissues in a rat model of repetitive grasping

  2016cites this paper
• Erratum to: The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells

  2016cites this paper
• Gpnmb/osteoactivin: an indicator and therapeutic target in tumor and nontumorous lesions.

  2016cites this paper
• Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells

  2016cites this paper
• The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells

  2015cites this paper
• Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer

  2015influential citation
• The Potential Role of the Glycoprotein Osteoactivin/Glycoprotein Nonmetastatic Melanoma Protein B in Pancreatic Cancer

  2015cites this paper
• The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells

  2015cites this paper
• Immunolocalization of dually phosphorylated MAPKs in dividing root meristem cells of Vicia faba, Pisum sativum, Lupinus luteus and Lycopersicon esculentum

  2015cites this paper
• Case studies and future applications in development

  2015cites this paper
• The Potential of Antibody Drug Conjugates in the Treatment of Breast Cancer

  2015cites this paper
• Small molecules for immunomodulation in cancer: a review.

  2014cites this paper
• Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

  2014cites this paper
• Lysosomal Stress in Obese Adipose Tissue Macrophages Contributes to MITF-Dependent Gpnmb Induction

  2014cites this paper
• GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity.

  2014cites this paper
• Identification of novel inflammatory serum biomarker signatures associated with pancreatic cancer and molecular characterization of antitumour agents over proliferation and apoptosos in vitro

  2014cites this paper
• Initial testing (stage 1) of glembatumumab vedotin (CDX‐011) by the pediatric preclinical testing program

  2014cites this paper
• Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer

  2013influential citation
• CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE)

  2013cites this paper
• Characterization of stromal cell-derived factor-1 (SDF-1) and glycoprotein nmb (GPNMB) in cardiac pathophysiology

  2013cites this paper
• Research and Development of Highly Potent Antibody-Based Drug Conjugates and Fusion Proteins for Cancer Therapy

  2012cites this paper
• Expression and immunolocalization of Gpnmb, a glioma-associated glycoprotein, in normal and inflamed central nervous systems of adult rats

  2012cites this paper
• Genomic Analysis of wig-1 Pathways

  2012cites this paper
• Gpnmb/osteoactivin, an attractive target in cancer immunotherapy.

  2012cites this paper
• Hematopoietic growth factor inducible neurokinin-1 (Gpnmb/Osteoactivin) is a biomarker of progressive renal injury across species.

  2011cites this paper
• SLC41A1 Mg(2+) transport is regulated via Mg(2+)-dependent endosomal recycling through its N-terminal cytoplasmic domain.

  2011cites this paper
• Impact actuel des produits naturels sur la découverte de nouveaux médicaments anticancéreux

  2010cites this paper
• GPNMB expression in uveal melanoma: a potential for targeted therapy

  2010cites this paper
• Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.

  2010cites this paper
• Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome‐specific and proteolytically released protein

  2010influential citation
• Functional roles of osteoactivin in normal and disease processes.

  2010cites this paper
• Emerging therapeutic targets in breast cancer bone metastasis.

  2010cites this paper
• [Current impact of natural products in the discovery of anticancer drugs].

  2010cites this paper
• ADAM10 Releases a Soluble Form of the GPNMB/Osteoactivin Extracellular Domain with Angiogenic Properties

  2010influential citation
• Inactivation of the FLCN Tumor Suppressor Gene Induces TFE3 Transcriptional Activity by Increasing Its Nuclear Localization

  2010cites this paper
• Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer

  2010cites this paper
• Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011‐vcMMAE antibody‐drug conjugate

  2008cites this paper
• Becker Digital

  year unknowninfluential citation